Symposium – Building International Consortia on parasitic diseases: the NMtrypl experience​ – 10th April

Some of the most deadly tropical infectious diseases are caused by protozoan parasites from the Trypanosomatidae family. These diseases – leishmaniasis, Chagas disease and Human African Trypanosomiasis represent a huge burden in the life of affected people, as well as public health problems in countries where the diseases are endemic. Drugs available for the treatment of these diseases are associated with severe toxicity, insufficient efficacy, inefficient delivery and increasing resistance, so new drugs are urgently needed.

 However, resources for drug discovery for neglected diseases are scarce and it is necessary to think out of the box to maximize efficiency and decrease costs in the discovery process. Multidisciplinary, international collaborative consortia are among the most efficient strategies for addressing the need of innovation in neglected diseases.

This symposium will introduce initiatives on multinational and multidisciplinary drug discovery consortia from the Seventh Framework Programme (FP7) of the European Commission, focusing on the New Medicines for Trypanosomatid Infections (NMTrypl) project. Opportunities for increased interaction between European and Brazilian laboratories will also be discussed.


NMTrypI Scientific Meeting

The New Medicine for Trypanosomatid Infections (NMTrypI) consortium uses a highly interdisciplinary approach to optimize new drugs against trypanosomes and Leishmania. The major objectives of this 3-year project are: i) development of at least 1-2 innovative, less toxic and safer drug candidates for Trypanosomatid infections compared to existing ones; (ii) early phase biomarkers for efficacy prediction (overall improved efficacy and safety). The next NMTrypl WP Leaders meeting will take place in CNPEM, Campinas, Brazil, from April 8th and 9th, 2015.